---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-24-000010"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:45:29.576400+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports Q4 2023 net loss $12M; CSO retiring March 29, 2024

## Summary
- Net loss of $12.0M in Q4 2023 ($37.4M full year) vs $11.9M in Q4 2022.
- Cash and equivalents $134.3M plus restricted cash $21.2M as of Dec 31, 2023.
- Cash runway extended through Q2 2025, including $17.7M ATM proceeds in early 2024.
- Collaboration revenue from Jazz fell to $1.5M Q4 from $7.3M year ago.
- CSO Cynthia Seidel-Dugan retiring effective March 29, 2024.

## SEC filing metadata
- accession: 0001785530-24-000010
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/0001785530-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/howl-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-24-000010
- JSON: https://secwatch.observer/filing/0001785530-24-000010.json
- Plain text: https://secwatch.observer/filing/0001785530-24-000010.txt

## Key facts
- Earnings Releases
  Werewolf Therapeutics, Inc. reported quarter ended December 31, 2023 results: revenue $1.5 million.
  - Period: quarter ended December 31, 2023
  - Revenue: $1.5 million
  - Result: reported results
  source text: Collaboration revenue was $1.5 million for the fourth quarter of 2023, compared to $7.3 million for the same period in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/0001785530-24-000010-index.htm
- Executive change
  Cynthia Seidel-Dugan departed as Chief Scientific Officer at Werewolf Therapeutics, Inc..
  - Action: retire
  - Role: Chief Scientific Officer
  source text: On March 3, 2024, Cynthia Seidel-Dugan, Ph.D., notified the Company of her intent to retire from her position as Chief Scientific Officer of the Company, effective as of March 29, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/0001785530-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.